JMP Securities Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $17

Moomoo NewsNov 21 19:31 ET · Ratings

Zevra Therapeutics Announces Availability of MIPLYFFA, First FDA-Approved Treatment for Niemann-Pick Disease Type C, Through AmplifyAssist Patient Support Program

Quiver QuantitativeNov 21 17:02 ET

Express News | Zevra Therapeutics Announces U.S. Commercial Availability of Miplyffa™ (Arimoclomol) for Treatment of Niemann-Pick Disease Type C

ReutersNov 21 16:51 ET

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA (Arimoclomol) for Treatment of Niemann-Pick Disease Type C

GlobeNewswireNov 21 16:51 ET

Zevra Therapeutics Gains Momentum With Miplyffa Approval and Market Expansion Potential in Rare Disease Treatment

TipRanksNov 21 07:16 ET

H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $20

Moomoo NewsNov 20 06:32 ET · Ratings